文献速递心律失常血脂与心血管预防心力衰竭与心肌病

ACTIVE试验中抗血小板治疗房颤患者复律前后血栓栓塞事件

Thromboembolic events around the time of cardioversion for atrial fibrillation in patients receiving antiplatelet treatment in the ACTIVE trials.
PubMed 文献 · Eur Heart J · 2019-01-01

在ACTIVE试验中随机接受阿司匹林或阿司匹林联合氯吡格雷的962例房颤患者中,复律前30天至复律后30天的血栓栓塞发生率为0.73%,而远离复律的随访期为0.16%(HR 4.1,95%CI 2.1-7.9)。复律前30天和复律后30天的发生率分别为0.47%和0.96%(HR 2.2,95%CI 0.7-7.1)。提示复律前后血栓栓塞风险升高可能不完全由复律本身导致,而与需复律患者的整体临床恶化混杂。

要点

  • 复律前后30天血栓栓塞风险较非复律期升高约4倍。
  • 复律后30天风险升高,无论是否接受口服抗凝或经食管超声。
  • 风险升高模式与心衰住院增加相似,提示混杂因素。

核心结论

  • 复律前30天至复律后30天血栓栓塞风险升高,但可能不完全由复律因果导致,而与患者整体临床恶化混杂。

研究设计与样本

  • ACTIVE试验中随机接受阿司匹林或阿司匹林联合氯吡格雷的962例房颤患者,比较复律前后30天与远离复律随访期的血栓栓塞发生率。

主要发现

  • 远离复律的30天血栓栓塞率为0.16%,复律前后30天为0.73%(HR 4.1,95%CI 2.1-7.9)。
  • 复律前30天血栓栓塞率为0.47%,复律后30天为0.96%(HR 2.2,95%CI 0.7-7.1)。
  • 复律前后心衰住院增加(HR 11.5,95%CI 6.8-19.4)。
  • 复律后30天血栓栓塞风险在口服抗凝或经食管超声患者中升高(HR 7.9,95%CI 2.8-22.4),未接受者亦升高(HR 4.8,95%CI 1.6-14.9),交互P=0.2。
  • 复律成功(HR 4.5,95%CI 2.0-10.5)和失败(HR 10.2,95%CI 2.3-44.9)均与风险升高相关。

临床怎么用

  • 复律前后应关注血栓栓塞风险,尤其对于临床状况恶化需复律的患者。
  • 抗血小板治疗患者复律前后血栓栓塞风险仍升高,需综合评估。

局限性

  • 研究为ACTIVE试验的事后分析,患者均接受抗血小板治疗,非口服抗凝人群。
  • 血栓栓塞风险升高与心衰住院增加模式相似,提示可能存在混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: It is unknown whether cardioversion of atrial fibrillation causes thromboembolic events or is a risk marker. To assess causality, we examined the temporal pattern of thromboembolism in patients having cardioversion. METHODS AND RESULTS: We studied patients randomized to aspirin or aspirin plus clopidogrel in the ACTIVE trials, comparing the thromboembolic rate in the peri-cardioversion period (30 days before until 30 days after) to the rate during follow-up, remote from cardioversion. Among 962 patients, the 30-day thromboembolic rate remote from cardioversion was 0.16%; while it was 0.73% in the peri-cardioversion period [hazard ratio (HR) 4.1, 95% confidence interval (CI) 2.1-7.9]. The 30-day thromboembolic rates in the periods immediately before and after cardioversion were 0.47% and 0.96%, respectively (HR 2.2, 95% CI 0.7-7.1). Heart failure (HF) hospitalization increased in the peri-cardioversion period (HR 11.5, 95% CI 6.8-19.4). Compared to baseline, the thromboembolic rate in the 30 days following cardioversion was increased both in patients who received oral anticoagulation or a transoesophageal echocardiogram prior to cardioversion (HR 7.9, 95% CI 2.8-22.4) and in those who did not (HR 4.8, 95% CI 1.6-14.9) (interaction P = 0.2); the risk was also increased with successful (HR 4.5; 95% CI 2.0-10.5) and unsuccessful (HR 10.2; 95% CI 2.3-44.9) cardioversion. CONCLUSIONS: Thromboembolic risk increased in the 30 days before cardioversion and persisted until 30 days post-cardioversion, in a pattern similar to HF hospitalization. These data suggest that the increased thromboembolic risk around the time of cardioversion may not be entirely causal, but confounded by the overall clinical deterioration of patients requiring cardioversion.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. McIntyre WF, Connolly SJ, Wang J, et al. Thromboembolic events around the time of cardioversion for atrial fibrillation in patients receiving antiplatelet treatment in the ACTIVE trials. Eur Heart J. 2019. PMID: 31377776. doi:10.1093/eurheartj/ehz521

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。